The stock will trade on upcoming Part A data readout (Q2 2026) and REVEAL pivotal trial interim analysis — these binary catalysts will determine BLA filing feasibility. The widening net loss is expected for a pre-revenue biotech advancing toward registration, but the cash runway into 2028 provides a long enough window. Monitor for the Part A safety/efficacy data release expected within weeks.
Price Chart
Executive Summary
Taysha Gene Therapies reported Q1 2026 financial results with a net loss of $42.4M ($0.12/share), wider than the $21.5M loss in Q1 2025, driven by increased R&D spending on BLA-enabling manufacturing and clinical trials. The key catalyst is the reaffirmed FDA alignment on the TSHA-102 BLA pathway, including potential submission based on the 6-month interim analysis from the REVEAL pivotal trial, with dosing completion expected in Q2 2026.
Key Financial Metrics
Key Facts
- Net loss of $42.4M ($0.12/share) for Q1 2026 vs $21.5M ($0.08/share) in Q1 2025
- Cash and cash equivalents of $276.6M as of March 31, 2026, expected to fund operations into 2028
- Reaffirmed FDA alignment on TSHA-102 BLA pathway, including potential submission based on 6-month interim analysis from REVEAL pivotal trial
- Dosing completion in REVEAL pivotal and ASPIRE trials expected in Q2 2026
- BLA-enabling PPQ campaign initiated in April 2026, completion expected in Q4 2026
- No treatment-related SAEs or DLTs in all patients treated as of May 2026 data cutoff
- R&D expenses increased to $33.8M from $15.6M year-over-year, driven by PPQ manufacturing and clinical trial costs
Financial Impact
Net loss widened by $20.9M year-over-year to $42.4M; cash burn rate increased significantly with R&D spending more than doubling
Risk Factors
- Clinical trial failure or disappointing efficacy data from Part A readout or REVEAL interim analysis
- Regulatory setback or FDA request for additional data delaying BLA submission
- Cash burn acceleration if PPQ campaign or clinical timelines extend beyond expectations
- Dilution risk from ATM program or future equity offerings to fund commercial launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-207633 |
| Document: d99032d8k.htm | 0001193125-26-207633 |
| Document: 0001193125-26-207633-index-headers.html | 0001193125-26-207633 |
| Document: 0001193125-26-207633-index.html | 0001193125-26-207633 |
| Document: 0001193125-26-207633.txt | 0001193125-26-207633 |
| 8-K Data (Synthetic) | 0001193125-26-207633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.66 (−27.17%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.66 (−26.42%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.66 (+26.42%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.66 (+24.88%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.66 (−15.18%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.66 (−25.60%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.66 (−25.95%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.66 (−30.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access